Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Inclusion Criteria: * Japanese subjects ≥ 20 years of age * ECOG Performance Status of 0 to 1 * Life expectancy of at least 12 weeks * Subjects with advanced, histologically or cytologically confirmed solid tumors, not amenable to any standard therapy, have no standard therapy available * Subjects whose fresh or archival tumor tissues are available * Measurable disease with at least one lesion that can be accurately measured in at least one dimension according to RECIST criteria (Version 1.1 or modified version) * Adequate bone marrow, liver, and renal function Exclusion Criteria: * Anticancer chemotherapy, experimental cancer therapy, or immunotherapy within 2 weeks of start of the first dose * Impaired cardiac function or clinically significant cardiac disease (i.e., congestive heart failure (CHF) NYHA Class III or IV) * Myocardial infarction or onset of unstable angina \< 3 months prior to general screening * Cardiac arrhythmias in the electrocardiogram that would interfere with QT/QTc interval measurement (LBBB (left bundle branch block), AV block, atrial fibrillation) * QTc \>470 ms, derived as the average of the 3 values measured by the ECG recorder's algorithm on the ECG triplicate * LVEF (left ventricular ejection fraction) \<50 % * Uncontrolled hypertension defined as systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 90 mmHg, despite optimal medical management * Known human immunodeficiency virus (HIV) infection * Subjects with an active hepa…